within Pharmacolibrary.Drugs.ATC.C;

model C05CA04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.13,
    Cl             = 1.9999999999999998e-05,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0011333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C05CA04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Troxerutin is a flavonoid derivative with vasoprotective properties, used for the treatment of chronic venous insufficiency, hemorrhoids, and related vascular disorders. It is used in some countries, primarily in Europe and Asia, but is not approved by the US FDA.</p><h4>Pharmacokinetics</h4><p>PK parameters estimated based on available secondary literature and related flavonoid drugs, as no direct clinical pharmacokinetic studies in humans are published for troxerutin.</p><h4>References</h4><ol><li><p>Xu, M, et al., &amp; Jin, Y (2016). Development and in vitro-in vivo evaluation of a water-in-oil microemulsion formulation for the oral delivery of troxerutin. <i>Drug development and industrial pharmacy</i> 42(2) 280–287. DOI:<a href=&quot;https://doi.org/10.3109/03639045.2015.1047849&quot;>10.3109/03639045.2015.1047849</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26165244/&quot;>https://pubmed.ncbi.nlm.nih.gov/26165244</a></p></li><li><p>Xin, X, et al., &amp; Zhao, G (2018). Biocatalytic synthesis of acylated derivatives of troxerutin: their bioavailability and antioxidant properties in vitro. <i>Microbial cell factories</i> 17(1) 130–None. DOI:<a href=&quot;https://doi.org/10.1186/s12934-018-0976-x&quot;>10.1186/s12934-018-0976-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30134913/&quot;>https://pubmed.ncbi.nlm.nih.gov/30134913</a></p></li><li><p>Auteri, A, et al., &amp; Delchambre, J (1994). Pharmacodynamics and pharmacokinetics of Veliten (rutine, alpha-tocopherol and ascorbic acid) in patients with chronic venous insufficiency. <i>International journal of clinical pharmacology research</i> 14(3) 95–100. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7883390/&quot;>https://pubmed.ncbi.nlm.nih.gov/7883390</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C05CA04;
